Entyvio (vedolizumab) has one of the more favorable safety profiles among biologic drugs used for inflammatory bowel disease. The most commonly reported side effects are everyday complaints like headaches, joint pain, nasal congestion, nausea, and upper respiratory infections. Four years of global post-marketing surveillance confirmed that adverse event patterns in the real world matched what was seen in clinical trials, with no new safety concerns emerging and most reported events being non-serious.1PubMed. The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn’s Disease: 4 Years of Global Post-marketing Data Still, because Entyvio works by targeting the immune system in the gut specifically, there are some distinctive risks and nuances worth understanding.
Why Entyvio’s Side-Effect Profile Differs From Other Biologics
Entyvio belongs to a class of biologics that blocks a protein called α4β7 integrin, which immune cells use to travel into the lining of the intestines. Because it targets the gut rather than suppressing the immune system body-wide, it tends to produce fewer systemic infections than drugs that dampen immune function everywhere. That gut selectivity is a double-edged sword, though: patients on Entyvio have a somewhat higher risk of gut-specific infections compared with people on anti-TNF drugs or ustekinumab, likely because the drug is pulling immune surveillance away from the intestinal lining.2European Journal of Gastroenterology & Hepatology. Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease Understanding this tradeoff is key to making sense of Entyvio’s side-effect list.
The Common, Day-to-Day Side Effects
An analysis of the FDA’s adverse event reporting system found that the side effects most often reported for Entyvio are the ones listed on its prescribing label: nasopharyngitis (a stuffy or runny nose), headache, joint pain, nausea, fever, upper respiratory tract infections, fatigue, cough, bronchitis, flu-like symptoms, back pain, rash, itching, sinusitis, sore throat, and pain in the arms or legs. When these known side effects were compared head-to-head against reports for anti-TNF drugs, none of them showed up at a higher rate for Entyvio. Compared with all other drugs in the reporting system, Entyvio did show a signal for joint-related symptoms, upper respiratory tract infections, and upper respiratory symptoms like sore throat.3PLoS ONE. Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system
In a matched comparison of older and younger patients, the most frequently reported problems were skin rash and shortness of breath in the older group, and rash and infections in the younger group. The rates were low enough that vedolizumab was considered well tolerated across age groups.4PubMed Central. Efficacy and safety of vedolizumab in elderly patients with inflammatory bowel disease: a matched case–control study Most people experience these side effects mildly or not at all, and they rarely force anyone to stop treatment.
Infection Risks in Context
Infection is the concern that looms largest with any biologic. With Entyvio, the overall picture is reassuring when measured against anti-TNF drugs. A large study found that the rate of serious infections was about 26 per 1,000 person-years for Entyvio users and about 23 per 1,000 person-years for anti-TNF users, a difference that was not statistically meaningful for the combined IBD population. For people with ulcerative colitis specifically, Entyvio was associated with a lower risk of serious infections than anti-TNF therapy.5Clinical Gastroenterology and Hepatology. Risk of Serious Infections in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Anti–Tumor Necrosis Factor Agents
The gut-specific infection that gets the most attention is Clostridioides difficile (C. diff), a bacterial infection that causes severe diarrhea and can be dangerous. In the phase 3 clinical trials, C. diff was the most frequently reported opportunistic infection, though the absolute numbers were small.6Inflammatory Bowel Diseases. Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting A meta-analysis pooling results across studies estimated the overall rate of C. diff infection among Entyvio-treated patients at about 1.3%, with serious cases occurring in roughly 0.4%.7PubMed Central. Risk of Clostridioides difficile infection in inflammatory bowel disease patients undergoing vedolizumab treatment: a systematic review and meta-analysis When researchers compared C. diff rates directly between Entyvio and anti-TNF drugs, one retrospective study found no difference, and another actually found a lower hazard of severe C. diff with Entyvio.8PubMed Central. Risk of gastrointestinal infections after initiating vedolizumab and anti-TNFα agents for ulcerative colitis Factors like older age, smoking, and use of additional immunosuppressants played a larger role in C. diff risk than the choice of biologic.9PubMed Central. Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study
Opportunistic Infections and PML
Opportunistic infections, the rare infections that strike when the immune system is compromised, occurred in about half a percent of patients in the controlled phase 3 trials and in about 2.3% during a longer-term follow-up study spanning thousands of patient-years. C. diff and cytomegalovirus (CMV) accounted for most of those cases. In the broader post-marketing setting, with roughly 114,000 patient-years of Entyvio exposure, the rate of serious opportunistic infections remained low, and most patients were able to continue treatment.10Inflammatory Bowel Diseases. Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting
The infection that patients often ask about is progressive multifocal leukoencephalopathy, or PML, a rare and severe brain infection. The concern exists because an older, related drug called natalizumab (which blocks immune cell migration more broadly) carries a real PML risk. But Entyvio’s gut-selective mechanism appears to leave brain immune surveillance intact. A systematic review and meta-analysis of drug-induced PML found zero cases attributable to vedolizumab, while natalizumab carried a risk of roughly 0.33 cases per 100 patients over a median observation of about 44 months.11PubMed. Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis An earlier analysis estimated that if Entyvio’s PML risk were comparable to natalizumab’s, roughly 30 cases should have been observed by mid-2016, yet none were found.12PubMed Central. What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn’s Disease Treated With Vedolizumab? For practical purposes, PML is not considered a realistic risk with Entyvio.
Liver Effects
Liver injury from Entyvio is extremely uncommon. In clinical trials, the frequency of abnormal liver enzyme tests was no different from placebo. Elevations of a liver enzyme called ALT to more than five times the upper limit of normal were rare, occurring in under 2% of patients and at similar rates in those receiving placebo. Hepatobiliary side effects in both trial and post-marketing data made up less than 1% of all adverse events and occurred in up to 5% of patients, most involving mild liver enzyme abnormalities rather than actual liver damage.13GE – Portuguese Journal of Gastroenterology. Vedolizumab-Induced Liver Injury A handful of case reports have described more serious liver injury, including cases resembling autoimmune hepatitis, but these are isolated. One case report described it as the first post-marketing case of significant hepatocellular injury linked to Entyvio.14PubMed Central. Vedolizumab-Induced Liver Injury Your doctor will likely monitor liver enzymes periodically, but liver toxicity is not a leading concern with this drug.
Cancer Risk Over the Long Term
Whether a biologic increases cancer risk is a question that only gets answered with years of follow-up data, and on this front, Entyvio looks clean. In the long-term safety study (GEMINI LTS), among nearly 1,800 patients followed for at least one year (totaling over 5,600 patient-years), the number of cancers observed was almost exactly what would be expected in a similar general population: 31 observed versus 29 expected.15PubMed Central. Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data Head-to-head comparisons with anti-TNF drugs told the same story. In one study, the cancer rate was about 12 per 1,000 patient-years for Entyvio users and about 9 per 1,000 patient-years for anti-TNF users, but after adjusting for age, sex, and other factors, the difference disappeared.16PubMed Central. Risk of Malignancy with Vedolizumab versus Tumor Necrosis Factor-α Antagonists in Patients with Inflammatory Bowel Diseases An updated long-term safety review confirmed no unexpected safety signals, including for cancer, in pregnancy, in pediatric and elderly populations, and in patients with a prior cancer history.17PubMed. An update on the safety of long-term vedolizumab use in inflammatory bowel disease
Immunogenicity and What Happens If You Stop and Restart
Like all biologic drugs, Entyvio can trigger your body to make antibodies against the medication itself, potentially reducing its effectiveness. For people who stay on the drug continuously, this happens infrequently: roughly 2.4% of patients in the long-term data developed anti-drug antibodies. The rate jumps considerably if treatment is interrupted and then resumed, with about 22% of re-treated patients testing positive for antibodies during the gap. The good news is that antibody levels tended to decrease once steady dosing resumed, and there was no relationship found between having these antibodies and experiencing infusion reactions.18PubMed Central. Vedolizumab Immunogenicity With Long-Term or Interrupted Treatment of Patients With Inflammatory Bowel Disease The takeaway for patients: staying on your scheduled doses consistently matters. If your doctor suggests a treatment break, know that restarting carries a slightly higher but manageable immunogenicity risk.
Surgery and Entyvio
If you need abdominal surgery while on Entyvio, the evidence on postoperative complications is mixed but generally reassuring. One early study reported significantly higher rates of surgical site infections in Entyvio-treated patients compared with both anti-TNF and non-biologic groups.19PubMed. Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Abdominal Operations for Inflammatory Bowel Disease However, a subsequent cohort study found no increase in perioperative complications with Entyvio compared to anti-TNF drugs, and even noted a trend toward fewer infectious complications in the Entyvio group.20Intestinal Research. Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study A meta-analysis that pulled these types of studies together found no significant differences in overall postoperative complications, infectious complications, surgical site infections, need for reoperation, or major surgical complications between Entyvio and anti-TNF therapy. For ulcerative colitis patients, the pooled data actually favored Entyvio over anti-TNF drugs.21Inflammatory Bowel Diseases. Systematic Review and Meta-analysis: Vedolizumab and Postoperative Complications in Inflammatory Bowel Disease The conflicting early data likely reflected the fact that patients switched to Entyvio often had more severe disease and previous biologic failures, making them sicker going into surgery. Most surgeons today do not consider Entyvio a reason to delay necessary operations.
Older Adults and Pregnancy
The side-effect profile in older adults mirrors what is seen in younger patients, with one caveat. A binational retrospective study found an increased risk of infections among elderly Entyvio users, but the authors attributed this largely to the patients’ age and underlying health conditions rather than to the drug itself.22PubMed Central. Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort study In a matched case-control study, the rates of specific side effects like rash, joint pain, infections, infusion reactions, and shortness of breath were comparable between older and younger patients.23PubMed Central. Efficacy and safety of vedolizumab in elderly patients with inflammatory bowel disease: a matched case–control study
For people who are pregnant or breastfeeding, the available data is encouraging. Case reports and the broader safety review suggest that continuing Entyvio during pregnancy carries adverse event rates similar to anti-TNF therapy, which has a well-established track record in pregnancy.24PubMed Central. Vedolizumab Safety During Pregnancy and Lactation in a Patient with Ulcerative Colitis: A Case Report This is particularly relevant because uncontrolled IBD during pregnancy carries its own significant risks, so the decision to continue a biologic is usually about balancing two sets of risks rather than choosing between treatment and no treatment.
Joint Pain and Other Symptoms Outside the Gut
Because Entyvio targets gut immunity specifically, some patients worry that symptoms outside the intestines, called extraintestinal manifestations, might not improve or could even worsen. The data on this is a bit of a mixed bag. A real-world study found that about a quarter of patients who started Entyvio with pre-existing extraintestinal symptoms saw complete resolution within 12 months. Joint pain (arthralgia) resolved in about 26% of those who had it, and peripheral joint inflammation improved in about a third. Skin lesions like erythema nodosum resolved in about 43%. On the flip side, conditions like axial spondyloarthritis and uveitis (eye inflammation) showed no resolution during the study period.25Inflammatory Bowel Diseases. Impact of Vedolizumab on Extraintestinal Manifestations in Inflammatory Bowel Disease: Results From a Descriptive, Retrospective, Real-world Study
An umbrella review comparing different IBD therapies noted that vedolizumab showed the lowest improvement rates for joint manifestations specifically, and that the incidence of new eye-related symptoms while on Entyvio was low at about 1%.26PubMed Central. The Effectiveness of Medical Therapies for Joint, Skin and Eye Extraintestinal Manifestations in IBD-An Umbrella Review If your primary complaint is joint pain or you have a history of eye inflammation alongside your IBD, this is worth discussing with your gastroenterologist, since other biologics with systemic immune effects may do a better job at addressing those symptoms.
How Entyvio Compares on Drug Discontinuation
One practical way to measure a drug’s tolerability is to look at how often people have to stop taking it because of side effects. In a retrospective comparison with adalimumab (Humira), the rate of side effects severe enough to cause drug withdrawal was roughly 5 per 100 patient-years for Entyvio versus about 13 per 100 patient-years for adalimumab, translating to a 76% lower risk of stopping treatment for side effects on Entyvio after adjusting for disease type and other medications.27Intestinal Research. Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation A separate study in biologic-naive ulcerative colitis patients found that the risk of discontinuing treatment due to adverse events was significantly lower for Entyvio compared with both adalimumab and infliximab.28PubMed. Comparative Long-Term Drug Survival of Vedolizumab, Adalimumab, and Infliximab in Biologic-Naïve Patients with Ulcerative Colitis Among the side effects that did lead to stopping the drug, noninfectious complaints outside the gut (like joint pain or skin issues) were actually more common than infections in the Entyvio group.
Vaccines While on Entyvio
Because Entyvio works locally in the gut rather than suppressing the whole immune system, you might expect it to leave vaccine responses intact. That seems to be largely true. In a study comparing vaccine responses in Entyvio-treated patients, anti-TNF-treated patients, and healthy controls, there was no significant difference between groups in the immune response to the pneumococcal vaccine. For the hepatitis B vaccine, Entyvio-treated patients actually had a higher response rate than those on anti-TNF therapy, with about 63% achieving adequate antibody levels compared to about 33% in the anti-TNF group. No serious adverse events or significant flares were triggered by the vaccinations.29Crohn’s & Colitis 360. The Immunogenicity of the Influenza, Pneumococcal, and Hepatitis B Vaccines in Patients With Inflammatory Bowel Disease Treated With Vedolizumab This is a practical advantage over more broadly immunosuppressive biologics, where vaccine effectiveness can be blunted. You should still follow your gastroenterologist’s guidance on the timing of vaccines, but you can generally expect them to work.
Drug Level Monitoring
Therapeutic drug monitoring, where your doctor checks the amount of Entyvio in your blood, is a growing area of interest but not yet standard practice for this drug the way it is for some anti-TNF therapies. One study found a modest association between Entyvio blood levels and biochemical markers of remission in the overall IBD group, but no clear link between drug levels and clinical remission, the symptoms you actually feel.30PubMed Central. Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment—TUMMY Study However, checking levels early in treatment may help identify patients with unusually fast drug clearance who could benefit from dose adjustments before being written off as non-responders.31Scientific Reports. The use of therapeutic drug monitoring for early identification of vedolizumab response in Saudi Arabian patients with inflammatory bowel disease If you are not responding to Entyvio after the initial loading doses, asking your doctor about checking drug levels is reasonable before switching to another biologic entirely.